Muscarinic M4 selective agonist shows promise in schizophrenia
Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication.
The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20mg dose.
It demonstrated a clinically meaningful and statistically significant reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6 with a placebo-adjusted mean reduction of 7.5 points and an 18.2-point reduction from baseline.
The once-daily 20mg dose also demonstrated a statistically significant improvement for additional endpoints, including improvement in the Clinical Global Impression of Severity (CGI-S) scale, Marder Factor Score – Positive Symptom Change, and Marder Factor Score – Negative Symptom Change.
“NBI-1117568 demonstrated a clinically meaningful and statistically significant reduction in PANSS scores and was well tolerated, importantly with minimal GI effects and no weight gain relative to placebo,” said Dr Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital of Harvard University. “As a selective M4 orthosteric agonist, the potential of NBI-1117568 as an option that could reduce symptoms of schizophrenia with fewer side effects would be a welcome alternative to current treatments for patients and caregivers.”
Neurocrine Biosciences’ muscarinic agonist portfolio also includes NBI-1117567, NBI-1117569, and NBI-1117570, which the company acquired the rights to develop and commercialise from Nxera Pharma (formerly Sosei Heptares).
“This Phase II dose-finding study delivered on our goal of identifying a once-daily, well tolerated dosing regimen with a compelling and competitive benefit-risk profile,” said Dr Eiry Roberts, Chief Medical Officer at Neurocrine Biosciences. “We recognise the significant need for new and innovative medicines to treat schizophrenia and look forward to advancing NBI-‘568, the first M4 selective agonist, into Phase III development early next year.”
Diana Spencer, Senior Digital Content Editor, DDW
